{"id":7127,"date":"2025-06-23T04:48:11","date_gmt":"2025-06-23T04:48:11","guid":{"rendered":"https:\/\/www.europesays.com\/us\/7127\/"},"modified":"2025-06-23T04:48:11","modified_gmt":"2025-06-23T04:48:11","slug":"senate-health-policy-holds-testimony-on-opioid-legislation","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/us\/7127\/","title":{"rendered":"Senate Health Policy Holds Testimony on Opioid Legislation"},"content":{"rendered":"<p>\t\t    \t\t<img width=\"300\" height=\"300\" src=\"https:\/\/www.europesays.com\/us\/wp-content\/uploads\/2025\/06\/MR-Headers_2024_Advoc-300x300.png\" class=\"attachment-medium size-medium wp-post-image\" alt=\"\" decoding=\"async\" fetchpriority=\"high\"  \/><\/p>\n<p>The Senate Health Policy Committee held testimony on legislation related to treating patients with opioid use disorder during the week of June 16.<\/p>\n<p><strong>Collectively, Senate Bills (SB) <\/strong><a href=\"https:\/\/www.legislature.mi.gov\/documents\/2025-2026\/billintroduced\/Senate\/pdf\/2025-SIB-0397.pdf\" rel=\"nofollow noopener\" target=\"_blank\"><strong>397<\/strong><\/a><strong>\u2013<\/strong><a href=\"https:\/\/www.legislature.mi.gov\/documents\/2025-2026\/billintroduced\/Senate\/pdf\/2025-SIB-0405.pdf\" rel=\"nofollow noopener\" target=\"_blank\"><strong>405<\/strong><\/a> <strong>make numerous changes to improve coverage and access for Michiganders to receive treatment for opioid use disorder.<\/strong> SBs <a href=\"https:\/\/www.legislature.mi.gov\/documents\/2025-2026\/billintroduced\/Senate\/pdf\/2025-SIB-0397.pdf\" rel=\"nofollow noopener\" target=\"_blank\">397<\/a>, <a href=\"https:\/\/www.legislature.mi.gov\/documents\/2025-2026\/billintroduced\/Senate\/pdf\/2025-SIB-0400.pdf\" rel=\"nofollow noopener\" target=\"_blank\">400<\/a>, <a href=\"https:\/\/www.legislature.mi.gov\/documents\/2025-2026\/billintroduced\/Senate\/pdf\/2025-SIB-0401.pdf\" rel=\"nofollow noopener\" target=\"_blank\">401<\/a>, <a href=\"https:\/\/www.legislature.mi.gov\/documents\/2025-2026\/billintroduced\/Senate\/pdf\/2025-SIB-0402.pdf\" rel=\"nofollow noopener\" target=\"_blank\">402<\/a> and <a href=\"https:\/\/www.legislature.mi.gov\/documents\/2025-2026\/billintroduced\/Senate\/pdf\/2025-SIB-0403.pdf\" rel=\"nofollow noopener\" target=\"_blank\">403<\/a> specifically apply commercial insurer and Medicaid coverage modifications to reduce delays and remove additional barriers in prescribing opioid-related treatment and dosages.<\/p>\n<p><a href=\"https:\/\/www.legislature.mi.gov\/documents\/2025-2026\/billintroduced\/Senate\/pdf\/2025-SIB-0398.pdf\" rel=\"nofollow noopener\" target=\"_blank\">SB 398<\/a> modifies opioid treatment program requirements under the Department of Licensing and Regulatory Affairs, while SBs <a href=\"https:\/\/www.legislature.mi.gov\/documents\/2025-2026\/billintroduced\/Senate\/pdf\/2025-SIB-0404.pdf\" rel=\"nofollow noopener\" target=\"_blank\">404<\/a>\u2013<a href=\"https:\/\/www.legislature.mi.gov\/documents\/2025-2026\/billintroduced\/Senate\/pdf\/2025-SIB-0405.pdf\" rel=\"nofollow noopener\" target=\"_blank\">405<\/a> would require nurses to carry naloxone in select schools. Lastly, <a href=\"https:\/\/www.legislature.mi.gov\/documents\/2025-2026\/billintroduced\/Senate\/pdf\/2025-SIB-0399.pdf\" rel=\"nofollow noopener\" target=\"_blank\">SB 399<\/a> amends the Public Health Code to specify that the term \u201cdrug paraphernalia\u201d does not include testing products.<\/p>\n<p>The MHA-supported bills now await a final vote in the Senate Health Policy Committee before moving to the full Senate chamber. <strong>The MHA Behavioral Health Integration Council reviewed and recommended changes for SBs 397, 398, 399, 400 and 402. <\/strong><\/p>\n<p>Members with additional questions should contact\u00a0the <a href=\"https:\/\/www.mha.org\/contact-mha-advocacy\/\" rel=\"nofollow noopener\" target=\"_blank\">MHA Advocacy Team<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"The Senate Health Policy Committee held testimony on legislation related to treating patients with opioid use disorder during&hellip;\n","protected":false},"author":3,"featured_media":7128,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[35],"tags":[210,1141,1142,67,132,68],"class_list":{"0":"post-7127","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-health-care","8":"tag-health","9":"tag-health-care","10":"tag-healthcare","11":"tag-united-states","12":"tag-unitedstates","13":"tag-us"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@us\/114730874963820947","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/7127","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/comments?post=7127"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/7127\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media\/7128"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media?parent=7127"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/categories?post=7127"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/tags?post=7127"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}